No Data
Keros Therapeutics Is Maintained at Buy by Truist Securities
Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating, Announces Target Price $43
Truist Slashes Price Target on Keros Therapeutics to $43 From $100, Keeps Buy Rating
Analyst's Buy Rating on Keros Therapeutics Driven by Strategic Partnerships and Market Potential
Oppenheimer Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $63
Oppenheimer Maintains Outperform on Keros Therapeutics, Lowers Price Target to $63
Tooleye3 OP : - YouTube